CRISPR director granted options on 13,000 shares
CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant covering 13,000 common shares.
Rhea-AI Filing Summary
CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant covering 13,000 common shares. The option has an exercise price of $51.84 per share and was awarded at no purchase cost to him on the grant date.
The option expires on June 5, 2036. According to the vesting terms, it becomes exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026 and the final installment vesting on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 13,000 shares
Grant/Award
1 txn
Insider
Treco Douglas A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 13,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct)
Footnotes (1)
- F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Key Figures
Option grant size: 13,000 shares
Exercise price: $51.84 per share
Expiration date: June 5, 2036
+3 more
6 metrics
Option grant size
13,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$51.84 per share
Conversion or exercise price of granted options
Expiration date
June 5, 2036
Expiration of stock option grant
Vesting start
June 30, 2026
First monthly installment vests
Vesting schedule length
12 monthly installments
Equal monthly vesting following grant date
Shares after transaction
13,000 options
Total options held from this grant after transaction
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 51.8400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"the options will vest and become exercisable in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting financial
"the last installment vests on the earlier of ... or (ii) the date of the 2027 Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CRISPR Therapeutics (CRSP) director Douglas Treco report?
Douglas A. Treco reported receiving a stock option grant for 13,000 common shares. The option was awarded at no purchase cost and reflects a compensation-related acquisition rather than an open-market share purchase or sale.
What is the exercise price of Douglas Treco’s new CRISPR Therapeutics (CRSP) options?
The granted stock options have an exercise price of $51.84 per share. This means Treco can buy up to 13,000 CRISPR Therapeutics common shares at $51.84 if and when the options vest and are exercised.
When do Douglas Treco’s CRISPR Therapeutics (CRSP) options start and finish vesting?
The options start vesting on June 30, 2026, in 12 equal monthly installments. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of CRISPR Therapeutics’ 2027 Annual Meeting.
When do Douglas Treco’s CRISPR Therapeutics (CRSP) stock options expire?
The stock options granted to Douglas A. Treco expire on June 5, 2036. After that expiration date, any unexercised portion of the 13,000-share option can no longer be used to buy CRISPR Therapeutics common shares.
Is Douglas Treco’s CRISPR Therapeutics (CRSP) Form 4 transaction a market buy or sell?
The Form 4 shows a grant, classified as a “Grant, award, or other acquisition.” It is a compensation-related award of options, not an open-market purchase or sale of CRISPR Therapeutics common shares.
How many CRISPR Therapeutics (CRSP) options does Douglas Treco hold after this grant?
Following this transaction, Douglas A. Treco holds 13,000 stock options directly from this award. These options each relate to one common share and follow the specified vesting schedule and 2036 expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
